Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2020 Dec;24(67):1–66. doi: 10.3310/hta24670

Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.

Colin R Simpson, Nazir I Lone, Kim Kavanagh, Tanya Englishby, Chris Robertson, Jim McMenamin, Beatrix von Wissman, Eleftheria Vasileiou, Christopher C Butler, Lewis D Ritchie, Rory Gunson, Jürgen Schwarze, Aziz Sheikh
PMCID: PMC7750866  PMID: 33256892

Abstract

BACKGROUND

There is good evidence of vaccine effectiveness in healthy individuals but less robust evidence for vaccine effectiveness in the populations targeted for influenza vaccination. The live attenuated influenza vaccine (LAIV) has recently been recommended for children in the UK. The trivalent influenza vaccine (TIV) is recommended for all people aged ≥ 65 years and for those aged < 65 years who are at an increased risk of complications from influenza infection (e.g. people with asthma).

OBJECTIVE

To examine the vaccine effectiveness of LAIV and TIV.

DESIGN

Cohort study and test-negative designs to estimate vaccine effectiveness. A self-case series study to ascertain adverse events associated with vaccination.

SETTING

A national linkage of patient-level general practice (GP) data from 230 Scottish GPs to the Scottish Immunisation & Recall Service, Health Protection Scotland virology database, admissions to Scottish hospitals and the Scottish death register.

PARTICIPANTS

A total of 1,250,000 people.

INTERVENTIONS

LAIV for 2- to 11-year-olds and TIV for older people (aged ≥ 65 years) and those aged < 65 years who are at risk of diseases, from 2010/11 to 2015/16.

MAIN OUTCOME MEASURES

The main outcome measures include vaccine effectiveness against laboratory-confirmed influenza using real-time reverse-transcription polymerase chain reaction (RT-PCR), influenza-related morbidity and mortality, and adverse events associated with vaccination.

RESULTS

Two-fifths (40%) of preschool-aged children and three-fifths (60%) of primary school-aged children registered in study practices were vaccinated. Uptake varied among groups [e.g. most affluent vs. most deprived in 2- to 4-year-olds, odds ratio 1.76, 95% confidence interval (CI) 1.70 to 1.82]. LAIV-adjusted vaccine effectiveness among children (aged 2-11 years) for preventing RT-PCR laboratory-confirmed influenza was 21% (95% CI -19% to 47%) in 2014/15 and 58% (95% CI 39% to 71%) in 2015/16. No significant adverse events were associated with LAIV. Among at-risk 18- to 64-year-olds, significant trivalent influenza vaccine effectiveness was found for four of the six seasons, with the highest vaccine effectiveness in 2010/11 (53%, 95% CI 21% to 72%). The seasons with non-significant vaccine effectiveness had low levels of circulating influenza virus (2011/12, 5%; 2013/14, 9%). Among those people aged ≥ 65 years, TIV effectiveness was positive in all six seasons, but in only one of the six seasons (2013/14) was significance achieved (57%, 95% CI 20% to 76%).

CONCLUSIONS

The study found that LAIV was safe and effective in decreasing RT-PCR-confirmed influenza in children. TIV was safe and significantly effective in most seasons for 18- to 64-year-olds, with positive vaccine effectiveness in most seasons for those people aged ≥ 65 years (although this was significant in only one season).

FUTURE WORK

The UK Joint Committee on Vaccination and Immunisation has recommended the use of adjuvanted injectable vaccine for those people aged ≥ 65 years from season 2018/19 onwards. A future study will be required to evaluate this vaccine.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN88072400.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 67. See the NIHR Journals Library website for further project information.

Plain language summary

In Scotland, a new type of influenza vaccine (live attenuated influenza vaccine), administered via the nose, was introduced in 2014/15 for all children aged between 2 and 11 years. It can be difficult to evaluate any changes in health as a result of new immunisation programmes, given that randomised controlled trials of vaccines are impractical and can also be seen as unethical. These changes are therefore typically not evaluated, making it difficult to inform future policy in this field. Observational studies can be used to assess the effects of health-care interventions without influencing the care that is provided or affecting the people who receive it. An evaluation (effectiveness and safety) of this change in the immunisation programme was conducted. The vaccine programme, an inactivated vaccine administered as an injection, for other groups for whom the evidence available is limited was also evaluated [i.e. for people aged ≥ 65 years and people aged < 65 years who have a medical condition (e.g. asthma) that puts them at risk of severe illness from influenza]. The findings support the view that the intranasal vaccine is effective and safe in preventing influenza in children. The injectable vaccine in people aged < 65 years who are more at risk of complications from flu was safe and effective. Lower effectiveness was found in people aged ≥ 65 years. Both the injectable vaccine and the intranasal vaccine have high levels of uptake in the population offered vaccination. When considering these results, the important limitation of bias in observational study designs should be noted [for instance, residual confounding, whereby it is not possible to measure a characteristic of those people receiving the vaccine (e.g. being healthier)], and this is accounted for in this analysis.

Full text of this article can be found in Bookshelf.

References

  1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179–86. https://doi.org/10.1001/jama.289.2.179 doi: 10.1001/jama.289.2.179. [DOI] [PubMed]
  2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086–96. https://doi.org/10.1016/j.vaccine.2007.03.046 doi: 10.1016/j.vaccine.2007.03.046. [DOI] [PubMed]
  3. Simpson CR, Lone NI, Kavanagh K, Robertson C, McMenamin J, von Wissman B, et al. Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. BMJ Open 2017;7:e014200 https://doi.org/10.1136/bmjopen-2016-014200 doi: 10.1136/bmjopen-2016-014200. [DOI] [PMC free article] [PubMed]
  4. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011;378:1917–30. https://doi.org/10.1016/S0140-6736(11)61051-9 doi: 10.1016/S0140-6736(11)61051-9. [DOI] [PubMed]
  5. Cauchemez S, Valleron AJ, Boëlle PY, Flahault A, Ferguson NM. Estimating the impact of school closure on influenza transmission from Sentinel data. Nature 2008;452:750–4. https://doi.org/10.1038/nature06732 doi: 10.1038/nature06732. [DOI] [PubMed]
  6. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLOS Med 2013;10:e1001527. https://doi.org/10.1371/journal.pmed.1001527 doi: 10.1371/journal.pmed.1001527. [DOI] [PMC free article] [PubMed]
  7. Department of Health and Social Care. CVI Statement on the Routine Annual Influenza Vaccination Programme. London: Department of Health and Social Care. URL: www.gov.uk/government/publications/jcvi-statement-on-the-routine-annual-influenza-vaccination-programme (accessed 17 June 2015).
  8. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:36–44. https://doi.org/10.1016/S1473-3099(11)70295-X doi: 10.1016/S1473-3099(11)70295-X. [DOI] [PubMed]
  9. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012;8:CD004879. https://doi.org/10.1002/14651858.CD004879.pub4 doi: 10.1002/14651858.CD004879.pub4. [DOI] [PMC free article] [PubMed]
  10. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010;7:CD001269. https://doi.org/10.1002/14651858.CD001269.pub4 doi: 10.1002/14651858.CD001269.pub4. [DOI] [PubMed]
  11. Valenciano M, Ciancio B, I-MOVE study team. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill 2012;17:20281. https://doi.org/10.2807/ese.17.39.20281-en doi: 10.2807/ese.17.39.20281-en. [DOI] [PubMed]
  12. Doshi P. Influenza: marketing vaccine by marketing disease. BMJ 2013;346:f3037. https://doi.org/10.1136/bmj.f3037 doi: 10.1136/bmj.f3037. [DOI] [PubMed]
  13. Simpson CR, Lone N, Kavanagh K, Ritchie LD, Robertson C, Sheikh A, et al. Trivalent inactivated seasonal influenza vaccine effectiveness for the prevention of laboratory confirmed influenza in a Scottish population 2000–2009. Euro Surveill 2015;20:ii–21043. https://doi.org/10.2807/1560-7917.ES2015.20.8.21043 doi: 10.2807/1560-7917.ES2015.20.8.21043. [DOI] [PubMed]
  14. Kavanagh K, Robertson C, McMenamin J. Assessment of the variability in influenza A(H1N1) vaccine effectiveness estimates dependent on outcome and methodological approach. PLOS ONE 2011;6:e28743. https://doi.org/10.1371/journal.pone.0028743 doi: 10.1371/journal.pone.0028743. [DOI] [PMC free article] [PubMed]
  15. Kavanagh K, Robertson C, McMenamin J. Estimates of influenza vaccine effectiveness in primary care in Scotland vary with clinical or laboratory endpoint and method – experience across the 2010/11 season. Vaccine 2013;31:4556–63. https://doi.org/10.1016/j.vaccine.2013.07.056 doi: 10.1016/j.vaccine.2013.07.056. [DOI] [PubMed]
  16. Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, SNIFFLE Study Investigators. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clin Immunol 2015;136:376–81. https://doi.org/10.1016/j.jaci.2014.12.1925 doi: 10.1016/j.jaci.2014.12.1925. [DOI] [PMC free article] [PubMed]
  17. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill 2013;18:20585. https://doi.org/10.2807/1560-7917.ES2013.18.37.20585 doi: 10.2807/1560-7917.ES2013.18.37.20585. [DOI] [PubMed]
  18. Information Services Division. Practice Team Information (PTI) Statistics. Edinburgh: National Services Scotland; 2010.
  19. McAlister FA, Murphy NF, Simpson CR, Stewart S, MacIntyre K, Kirkpatrick M, et al. Influence of socioeconomic deprivation on the primary care burden and treatment of patients with a diagnosis of heart failure in general practice in Scotland: population-based study. BMJ 2004;328:1110. https://doi.org/10.1136/bmj.38043.414074.EE doi: 10.1136/bmj.38043.414074.EE. [DOI] [PMC free article] [PubMed]
  20. Whitelaw FG, Nevin SL, Milne RM, Taylor RJ, Taylor MW, Watt AH. Completeness and accuracy of morbidity and repeat prescribing records held on general practice computers in Scotland. Br J Gen Pract 1996;46:181–6. [PMC free article] [PubMed]
  21. Information Services Division. Scottish Immunisation & Recall System. URL: www.isdscotland.org/Health-Topics/Child-Health/Child-Health-Programme/Scottish-Immunisation-Recall-System.asp (accessed 25 November 2015).
  22. Health Protection Scotland. Surveillance Data and Systems. Glasgow: Health Protection Scotland. URL: https://hpspubsrepo.blob.core.windows.net/hps-website/nss/2104/documents/1_2012-05-17.pdf (accessed 17 June 2015).
  23. Information Services Division. NHS Hospital Data Quality: Towards Better Data from Scottish Hospitals. Edinburgh: ISD Publications Scotland; 2007.
  24. Kendrick S, Clarke J. The Scottish Record Linkage System. Health Bull 1993;51:72–9. [PubMed]
  25. Scottish Public Health Observatory. Overview of Key Data Sources: ISD Linked Database. Edinburgh: National Services Scotland; 2010.
  26. Health Protection Scotland. Influenza Surveillance Systems. Glasgow: Health Protection Scotland. URL: https://hpspubsrepo.blob.core.windows.net/hps-website/nss/2524/documents/1_2009-05-19.pdf (accessed 23 November 2015).
  27. Simpson CR, Lone N, McMenamin J, Gunson R, Robertson C, Ritchie LD, Sheikh A. Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study. Health Technol Assess 2015;19(79). https://doi.org/10.3310/hta19790 doi: 10.3310/hta19790. [DOI] [PMC free article] [PubMed]
  28. Chief Medical Officer. Seasonal Influenza Vaccination Programme 2015–16. Edinburgh: National Services Scotland; 2015.
  29. Influenza (updated November 2011). In Salisbury D, Ramsay M, Noakes K, editors. Immunisation Against Infections Disease. London: The Stationery Office; 2006. pp. 185–204.
  30. Lone NI, Simpson C, Ritchie LD, Robertson C, Sheikh A, McMenamin J, et al. Seasonal Influenza Vaccine Effectiveness in the community (SIVE): exploitation of a unique national linked dataset. BMJ Open 2012;15:e001019. https://doi.org/10.1136/bmjopen-2012-001019 doi: 10.1136/bmjopen-2012-001019. [DOI] [PMC free article] [PubMed]
  31. Wallace LA, McAulay KA, Douglas JD, Elder AG, Stott DJ, Carman WF. Influenza diagnosis: from dark isolation into the molecular light. West of Scotland Respiratory Virus Study Group. J Infect 1999;39:221–6. https://doi.org/10.1016/S0163-4453(99)90053-1 doi: 10.1016/S0163-4453(99)90053-1. [DOI] [PubMed]
  32. Gunson RN, Bennett S, Maclean A, Carman WF. Using multiplex real time PCR in order to streamline a routine diagnostic service. J Clin Virol 2008;43:372–5. https://doi.org/10.1016/j.jcv.2008.08.020 doi: 10.1016/j.jcv.2008.08.020. [DOI] [PMC free article] [PubMed]
  33. National Statistics. Scottish Index of Multiple Deprivation: 2009 General Report. Edinburgh: Scottish Government National Statistics Publications; 2009.
  34. Scottish Government. Scottish Government Urban Rural Classification. Edinburgh: Scottish Government. URL: www.gov.scot/Topics/Statistics/About/Methodology/UrbanRuralClassification (accessed 14 August 2018).
  35. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83. https://doi.org/10.1016/0021-9681(87)90171-8 doi: 10.1016/0021-9681(87)90171-8. [DOI] [PubMed]
  36. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29:891–8. https://doi.org/10.1093/ije/29.5.891 doi: 10.1093/ije/29.5.891. [DOI] [PubMed]
  37. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1. https://doi.org/10.1186/1471-2296-11-1 doi: 10.1186/1471-2296-11-1. [DOI] [PMC free article] [PubMed]
  38. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, Belongia EA. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 2014;59:1375–85. https://doi.org/10.1093/cid/ciu680 doi: 10.1093/cid/ciu680. [DOI] [PMC free article] [PubMed]
  39. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–15 season. Clin Infect Dis 2016;63:21–32 https://doi.org/10.1093/cid/ciw176 doi: 10.1093/cid/ciw176. [DOI] [PMC free article] [PubMed]
  40. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007;7:658–66. https://doi.org/10.1016/S1473-3099(07)70236-0 doi: 10.1016/S1473-3099(07)70236-0. [DOI] [PubMed]
  41. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998;54:948–63. https://doi.org/10.2307/2533848 doi: 10.2307/2533848. [DOI] [PubMed]
  42. Wong K, Campitelli MA, Stukel TA, Kwong JC. Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med 2012;172:484–91. https://doi.org/10.1001/archinternmed.2011.2038 doi: 10.1001/archinternmed.2011.2038. [DOI] [PubMed]
  43. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000;29:722–9. https://doi.org/10.1093/ije/29.4.722 doi: 10.1093/ije/29.4.722. [DOI] [PubMed]
  44. Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, Kolczak MS, et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol 2006;59:808–18. https://doi.org/10.1016/j.jclinepi.2005.11.012 doi: 10.1016/j.jclinepi.2005.11.012. [DOI] [PubMed]
  45. Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 2004;22:2064–70. https://doi.org/10.1016/j.vaccine.2004.01.017 doi: 10.1016/j.vaccine.2004.01.017. [DOI] [PubMed]
  46. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009;27:2114–20. https://doi.org/10.1016/j.vaccine.2009.01.125 doi: 10.1016/j.vaccine.2009.01.125. [DOI] [PubMed]
  47. Simpson CR, Lone N, Kavanagh K, Ritchie LD, Robertson C, Sheikh A, et al. Seasonal Influenza Vaccine Effectiveness (SIVE): an observational retrospective cohort study – exploitation of a unique community-based national-linked database to determine the effectiveness of the seasonal trivalent influenza vaccine. Health Serv Deliv Res 2013;1(10). [PubMed]
  48. Kotz D, Viechtbauer W, Simpson C, van Schayck OC, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med 2015;3:761–8. https://doi.org/10.1016/S2213-2600(15)00320-3 doi: 10.1016/S2213-2600(15)00320-3. [DOI] [PMC free article] [PubMed]
  49. Health Protection Scotland. Influenza Surveillance Systems. Glasgow: Health Protection Scotland. URL: www.hps.scot.nhs.uk/a-to-z-of-topics/influenza (accessed 1 April 2016).
  50. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med 2010;103:98–106. https://doi.org/10.1258/jrsm.2009.090348 doi: 10.1258/jrsm.2009.090348. [DOI] [PMC free article] [PubMed]
  51. Hardelid P, Rait G, Gilbert R, Petersen I. Factors associated with influenza vaccine uptake during a universal vaccination programme of preschool children in England and Wales: a cohort study. J Epidemiol Community Health 2016;70:1082–7. https://doi.org/10.1136/jech-2015-207014 doi: 10.1136/jech-2015-207014. [DOI] [PubMed]
  52. Coupland C, Harcourt S, Vinogradova Y, Smith G, Joseph C, Pringle M, Hippisley-Cox J. Inequalities in uptake of influenza vaccine by deprivation and risk group: time trends analysis. Vaccine 2007;25:7363–71. https://doi.org/10.1016/j.vaccine.2007.08.032 doi: 10.1016/j.vaccine.2007.08.032. [DOI] [PubMed]
  53. Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 2009;58:446–58. https://doi.org/10.1016/j.jinf.2009.04.001 doi: 10.1016/j.jinf.2009.04.001. [DOI] [PubMed]
  54. Health Protection Scotland. Monthly National Influenza Report Week Ending 8 May 2016. Glasgow: Health Protection Scotland. URL: www.hps.scot.nhs.uk/resourcedocument.aspx?id=4356 (accessed 17 June 2018).
  55. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill 2016;21:pii–30348. https://doi.org/10.2807/1560-7917.ES.2016.21.38.30348 doi: 10.2807/1560-7917.ES.2016.21.38.30348. [DOI] [PMC free article] [PubMed]
  56. Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, et al. 2014–2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis 2016;63:1564–73. https://doi.org/10.1093/cid/ciw635 doi: 10.1093/cid/ciw635. [DOI] [PMC free article] [PubMed]
  57. Centers for Disease Control and Prevention (CDC). ACIP Votes Down Use of LAIV for 2016–2017 Flu Season. Media Statement. Atlanta, GA: CDC; 2016. URL: www.cdc.gov/media/releases/2016/s0622-laiv-flu.html (accessed 17 June 2018).
  58. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, McLean HQ. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016;16:942–51. https://doi.org/10.1016/S1473-3099(16)00129-8 doi: 10.1016/S1473-3099(16)00129-8. [DOI] [PubMed]
  59. Wu NC, Zost SJ, Thompson AJ, Oyen D, Nycholat CM, McBride R, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLOS Pathog 2017;13:e1006682. https://doi.org/10.1371/journal.ppat.1006682 doi: 10.1371/journal.ppat.1006682. [DOI] [PMC free article] [PubMed]
  60. Cobey S, Gouma S, Parkhouse K, Chambers BS, Ertl HC, Schmader KE, et al. Poor immunogenicity, not vaccine strain egg adaptation, may explain the low H3N2 influenza vaccine effectiveness in 2012–13. Clin Infect Dis 2018;67:327–33. https://doi.org/10.1093/cid/ciy097 doi: 10.1093/cid/ciy097. [DOI] [PMC free article] [PubMed]
  61. Joint Centre for Vaccination and Immunisation. Draft Minute of the Meeting on 7 February 2018. URL: https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/284102495624 (accessed 29 May 2018).
  62. Braeckman T, Van Herck K, Meyer N, Pirçon JY, Soriano-Gabarró M, Heylen E, et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ 2012;345:e4752. https://doi.org/10.1136/bmj.e4752 doi: 10.1136/bmj.e4752. [DOI] [PMC free article] [PubMed]
  63. Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 2008;197(Suppl. 2):82–9. https://doi.org/10.1086/522145 doi: 10.1086/522145. [DOI] [PubMed]
  64. Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis 2016;213:1872–5. https://doi.org/10.1093/infdis/jiw047 doi: 10.1093/infdis/jiw047. [DOI] [PubMed]
  65. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness in pandemic influenza – primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol Assess 2010;14(34). https://doi.org/10.3310/hta14340-05 doi: 10.3310/hta14340-05. [DOI] [PubMed]
  66. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study. Lancet Infect Dis 2012;12:696–702. https://doi.org/10.1016/S1473-3099(12)70133-0 doi: 10.1016/S1473-3099(12)70133-0. [DOI] [PubMed]
  67. Pebody RG, Green HK, Andrews N, Zhao H, Boddington N, Bawa Z, et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. Euro Surveill 2014;19:20823. https://doi.org/10.2807/1560-7917.ES2014.19.22.20823 doi: 10.2807/1560-7917.ES2014.19.22.20823. [DOI] [PubMed]

RESOURCES